BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Earnings

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Thursday, May 7, 2026, after the close of U.S.

Related news

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-08-06 20:15 EST

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-08-03 12:00 EST

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

CTMXCytomX Therapeutics, Inc.2026-07-30 12:00 EST

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

CTMXCytomX Therapeutics, Inc.2026-07-27 12:00 EST

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

CTMXCytomX Therapeutics, Inc.2026-06-03 12:00 EST

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

Stock data

Close
3.28 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States